Article
Molecular and immune profiling of HER2-low, HER2 ultra-low, and HER2-null male breast cancer.
Breast (Edinburgh, Scotland) - 1 Oct 2026
Trapani Dario, Deshmukh Sachin Kumar, Wu Sharon, Xiu Joanne, Jayachandran Priya, Gandhi Shipra, Lin Nancy U, Curigliano Giuseppe, Spanheimer Philip M, Abravanel Daniel L, Radovich Milan, Lustberg Maryam, Graff Stephanie L, Sledge George W, Tolaney Sara M, Leone José P
Abstract excerpt
BACKGROUND: HER2 expression is described along a biological continuum from null to positive and serves as a critical biomarker for therapeutic guidance in breast cancer (BC). While HER2-low and ultra-low categories have emerged as actionable targets for antibody-drug conjugates (ADCs) in female BC, their molecular and immune characteristics remain largely unexplored in male breast cancer. METHODS: We profiled 214...
Read the complete abstract on PubMedTopics
- Male
- Humans
- Breast Neoplasms, Male
- Erb-b2 Receptor Tyrosine Kinases
- Biomarkers, Tumor